The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
He brings extensive cross-functional expertise built through leadership roles
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
